Effect of daratumumab treatment on helper and cytotoxic T-cell counts. (A) Longitudinal data representation of the percent change from baseline of absolute CD3⁺, CD4⁺, and CD8⁺ T-cell counts over time in PB; lines represent connected data points of individual patients that are colored by best overall clinical response: blue, sCR; orange, VGPR; brown, PR; yellow, SD; green, MR. The black bold line shows the overall median percent change over time. Only visits with >2 data points are shown. (B) Median (range) percent change from baseline in BM T cells (as a percentage of lymphocytes) of daratumumab-treated patient.